Pacira biosciences, inc. (PCRX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating activities:
Net income (loss)

8,159

-4,888

-6,087

2,730

-2,771

8,285

-640

2,564

-10,680

4,595

-7,597

-19,743

-19,866

-3,972

-22,165

-7,958

-3,854

-2,498

3,086

8

1,260

-13,716

-3,004

-5,037

-11,477

-11,956

-14,784

-14,031

-23,138

-16,346

-15,745

-8,296

-11,894

-15,283

-9,508

-8,762

-9,775

Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation of fixed assets and amortization of intangible assets

4,821

5,090

5,605

5,281

3,600

4,051

3,504

2,848

2,762

3,659

3,361

3,709

3,104

3,260

3,278

3,216

3,165

3,119

2,830

2,783

2,743

10,035

2,392

2,333

2,603

1,700

1,330

1,286

1,431

1,446

1,417

1,405

1,380

1,284

1,029

1,011

990

Amortization of debt issuance costs

439

434

429

424

420

404

400

395

391

364

360

356

168

120

119

120

120

120

120

119

122

487

122

121

122

122

121

122

94

-61

-62

-60

-56

-56

-50

-7

28

Amortization of debt discount

3,594

3,530

3,467

3,404

3,345

3,287

3,229

3,170

3,113

3,058

3,003

2,951

1,411

1,022

1,022

1,022

1,022

1,022

1,022

1,023

1,035

4,139

1,035

1,034

1,035

1,035

1,034

1,035

855

260

261

207

103

104

249

98

1,193

Loss on disposal and impairment of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-158

-

-

-

-

-

-

-3,398

-

-

-

-

-

-

-

-

Gain (Loss) on Extinguishment of Debt

-

-

-

-

-

-

-

-

-

0

0

-11

-3,721

0

0

0

0

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal and impairment of fixed assets

-22

-

-841

-157

0

-

0

0

-10

-

-109

-1,893

-137

-

0

0

0

-

-

-

-

-

0

-149

-8

-

-62

31

0

-

-

-

-

-

-

-

-

Stock-based compensation

8,847

9,189

9,244

7,783

7,434

8,186

8,107

7,047

8,385

8,194

8,663

7,344

7,400

7,732

7,361

7,665

8,490

9,728

8,827

7,296

7,517

24,822

7,687

5,537

3,975

3,286

3,777

2,225

2,225

1,556

1,469

1,039

712

528

442

551

972

Changes in contingent consideration

-3,874

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on investment

-3,971

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-1,509

-124

-339

2,168

-1,633

-342

977

998

-1,523

-268

-56

1,847

-1,299

-387

-382

2,069

-1,314

Accounts receivable, net

-8,542

4,957

1,426

375

1,766

3,734

-1,375

4,438

-798

4,637

-446

-235

-2,235

3,172

-1,886

2,750

46

-64

1,638

-230

2,145

7,776

-28

4,576

1,379

4,819

2,016

2,512

891

1,893

-755

2,354

-1,253

617

441

-755

619

Inventories, net

1,370

-1,941

7,448

4,059

-1,540

3,684

2,831

2,010

-1,368

2,299

5,510

3,291

-967

-6,198

-23,440

-2,828

2,099

5,513

7,363

12,505

7,001

13,706

4,468

3,830

-193

-49

1,385

3,461

-1,317

171

2,607

4,221

3,833

-422

-217

106

173

Prepaid expenses and other assets

3,674

1,434

1,288

-481

1,644

1,816

1,514

-1,312

1,210

258

-1,885

1,202

-3,051

-825

4,294

-3,009

2,917

1,360

1,679

-660

-372

1,621

364

569

-237

334

-73

-157

868

-102

591

-64

-366

-300

249

322

337

Accounts payable, accrued expenses and income taxes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,967

-2,431

-6,227

7,866

-1,082

7,861

-5,679

15,349

4,334

6,757

-1,531

3,201

3,161

3,098

162

-5,463

8,105

-643

-613

1,852

620

-751

828

Royalty interest obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

276

970

264

196

181

98

131

101

104

38

716

229

93

380

543

816

76

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-356

-

-356

-357

-356

6,713

-356

7,678

-252

257

-243

-243

-243

-817

-3,478

-6,317

-6,166

1,269

-671

-533

1,000

Accounts payable

2,868

-2,651

2,150

121

-1,442

827

1,426

-2,932

106

2,814

749

905

1,244

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and income taxes payable

-24,700

16,209

2,160

7,010

-5,166

5,274

2,232

5,320

-7,623

2,003

-6,758

10,702

-2,300

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-1,173

-5,904

-577

-194

-51

85

487

434

-109

-556

-1,519

-214

-1,266

-1,454

-1,930

2,464

-419

3,370

952

9

29

2,526

879

985

278

312

203

82

450

-23

-41

-39

-3

-695

26

28

668

Payment of contingent consideration to MyoScience, Inc. securityholders

264

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by operating activities

6,208

25,904

18,354

22,763

3,499

21,220

16,629

13,710

-2,689

16,931

-2,808

3,656

6

17,349

11,684

7,541

-3,121

16,994

4,719

7,178

-870

26,564

8,360

8,218

-4,736

-6,902

-9,837

-13,310

-13,789

-21,179

-11,177

-20,229

-17,545

-7,596

-8,494

-10,923

-3,987

Investing activities:
Purchases of fixed assets

6,724

4,497

1,592

2,052

2,018

2,243

4,453

2,634

5,184

5,076

5,419

5,155

3,616

4,882

3,906

8,868

7,053

9,083

11,506

11,832

7,874

22,984

4,330

6,023

3,808

2,804

4,696

1,740

2,932

4,732

6,258

4,366

2,901

2,483

1,649

1,203

832

Purchases of investments

72,610

98,393

78,131

119,272

22,688

180,505

1

52,169

130,580

66,735

161,226

94,449

180,342

34,425

36,600

53,947

67,843

63,885

32,276

42,984

49,937

164,303

87,418

34,046

18,946

12,185

14,894

15,435

71,785

-

-

-

-

-

-

-

-

Sales of investments

50,768

71,103

85,348

59,830

103,187

59,586

101,040

116,798

127,764

97,751

141,180

40,568

42,214

34,457

37,105

45,140

54,925

82,256

36,805

38,548

59,631

80,286

11,075

24,169

32,772

31,000

23,764

12,050

18,750

27,170

5,950

19,629

371

-

-

-

-

Payment of contingent consideration

-

-

-

-

-

1

2,127

2,422

2,293

2,241

2,013

2,114

2,092

2,067

9,919

1,967

1,904

1,992

1,765

1,742

1,620

13,433

9,528

1,193

999

790

559

398

284

-

-

-

-

-

-

-

-

Proceeds from follow-on public offering, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

110,452

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-28,566

-30,795

5,625

-181,799

78,481

-123,163

94,459

59,573

-10,293

8,699

-27,478

-61,150

-143,836

-6,917

-13,320

-19,642

-21,875

7,296

-8,742

-18,010

200

-120,434

-101,185

-30,574

9,019

15,221

3,615

-5,523

-56,251

22,359

-1,809

-47,542

-2,530

-11,768

-2,565

-20,958

-832

Financing activities:
Proceeds from exercises of stock options

3,455

3,478

1,423

2,467

1,101

2,696

2,982

1,073

419

1,474

2,691

1,761

852

570

769

1,390

3,041

1,275

1,823

2,928

4,047

7,239

2,381

1,387

1,964

813

979

1,187

877

237

250

230

153

-

-

0

1

Proceeds from shares issued under employee stock purchase plan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,184

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from initial public offering, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

38,016

Proceeds from issuance of 2022 convertible senior notes

-

-

-

-

-

-

-

-

-

0

0

0

345,000

0

0

0

0

-

-

-

-

-

-

-

-

0

0

0

120,000

-

-

-

-

-

-

-

-

Repayment of 2019 convertible senior notes

0

0

0

0

338

-

0

0

0

0

2

479

117,712

0

0

4

0

-

-

-

-

-

-

-

-

0

0

0

27,500

0

0

25,565

685

-

-

-

-

Payment of debt issuance and financing costs

-

-

-

-

-

-

-

-

-

0

0

0

11,000

0

0

0

0

-

-

-

-

-

-

-

-

0

0

0

7,191

0

0

1,017

348

-

-

-

-

Conversion premium on 2019 convertible senior notes

0

-233

0

0

233

0

0

0

0

0

1

0

284

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of contingent consideration to MyoScience, Inc securityholders

4,736

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

-1,281

-2,020

1,423

3,737

530

3,528

2,982

2,025

419

2,280

2,688

2,338

216,856

1,070

769

2,381

3,041

2,172

1,823

2,657

4,047

118,875

2,381

111,794

1,964

813

979

1,187

86,186

237

250

64,003

-880

49,130

11

0

38,017

Net (decrease) increase in cash and cash equivalents

-23,639

-6,911

25,402

-155,299

82,510

-98,415

114,070

75,308

-12,563

27,910

-27,598

-55,156

73,026

11,502

-867

-9,720

-21,955

26,462

-2,200

-8,175

3,377

25,005

-90,444

89,438

6,247

9,132

-5,243

-17,646

16,146

1,417

-12,736

-3,768

-20,955

29,766

-11,048

-31,881

33,198

Supplemental cash flow information:
Cash paid for interest

0

4,097

0

4,097

5

4,097

6

0

4,102

0

4,512

4

2,380

0

1,926

0

1,926

0

1,927

0

2,297

5,193

2,290

332

2,251

343

2,311

262

584

939

1,008

1,114

1,168

1,166

1,213

1,185

1,175

Cash paid for income taxes, net of refunds

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

34

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Initial public offering costs paid in 2010

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

907

Non-cash investing and financing activities:
Issuance of common stock from conversion of 2019 convertible senior notes

-

-

-

-

-

-

-

-

-

5,368

0

494

120,466

0

0

0

0

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income Taxes Paid, Net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12

99

142

-

40

-1

160

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Retirement of equity component of 2019 convertible senior notes

-

-

-

-

-

-

-

-

-

-

-2

-515

-125,811

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity component of the 2022 convertible senior notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

0

0

24,936

-

-

-

-

-

-

-

-

Net decrease in accrued fixed assets

423

1,788

-2,345

645

37

-228

2,162

-2,265

233

5,243

-760

-1,115

-1,179

-974

-477

-892

1,554

-1,202

-1,555

2,787

1,363

-1,095

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of notes to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

51,222

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

6